Â鶹Éç

Genetic Classification and Serologic Evaluation in Duchenne Muscular Dystrophy

Written by Margaret Anne Rockwood | Last updated June 3rd, 2026
Medically reviewed by Daniel Guillen, MD

Ìý

Genetic Classification and Serologic Evaluation in Duchenne Muscular Dystrophy

Diagnosis of Duchenne muscular dystrophy (Â鶹Éç) has evolved from reliance on histopathologic confirmation to a predominantly molecular approach, with serologic testing serving as an important screening tool and genetic testing providing definitive diagnosis.

Understanding the relationship between laboratory evaluation and genetic classification is essential for accurate diagnosis, prognostication, family counseling, and eligibility for mutation-specific therapies and clinical trials.

The modern diagnostic approach follows a clear division of roles:

Advances in molecular diagnostics have significantly reduced the need for muscle biopsy, shifting Â鶹Éç diagnosis toward a noninvasive, genetics-first model.

Serologic Evaluation: Role and Limitations

Creatine Kinase (CK) as a Screening Tool

Although genetic testing confirms the diagnosis, serum creatine kinase (CK) remains the most important initial laboratory test in suspected Â鶹Éç.

CK is released into the bloodstream following muscle fiber breakdown. In Â鶹Éç:

• CK levels are typically elevated to 10–100 times the upper limit of normal and may be even higher early in disease
• Elevation may occur before the onset of clinical symptoms, making CK a valuable early screening biomarker

CK testing is inexpensive, widely available, and highly sensitive for muscle pathology. It is often the first abnormal laboratory finding in children with Â鶹Éç.

However, CK has important limitations:

• CK elevation is nonspecific and reflects muscle injury rather than etiology
• It cannot distinguish Â鶹Éç from other muscular dystrophies or myopathies

Therefore, CK is highly useful for screening but is not diagnostic and must always be followed by molecular testing.

Additional Serum Markers

Other laboratory abnormalities may include:

• Elevated transaminases (AST and ALT), often reflecting muscle breakdown rather than primary liver disease
• Mild elevation in lactate dehydrogenase (LDH)

These findings can mimic hepatic disease, and lead to unnecessary evaluation unless muscular dystrophy is considered.

Molecular Basis and Genetic Classification

Once CK and clinical findings suggest myopathy, genetic testing is performed to confirm the diagnosis and classify the mutation.

Identifying the Dystrophin Gene Abnormality

Â鶹Éç results from mutations in the dystrophin (Â鶹Éç) gene located on chromosome Xp21, one of the largest genes in the human genome. Loss of functional dystrophin disrupts the dystrophin-associated protein complex, causing:

• Sarcolemmal instability
• Repeated muscle fiber injury and necrosis
• Progressive replacement of muscle tissue with fat and fibrosis

Genetic classification is based on:

• Type of mutation
• Location of the mutation within the gene
• Whether the mutation disrupts the reading frame (predictive of phenotype in most, but not all, dystrophinopathies)

This distinction is critical because reading-frame disruption generally produces Duchenne muscular dystrophy, while preservation of the reading frame usually produces Becker muscular dystrophy.ÌýThere are also differences in severity, progression and central nervous system symptoms associated with specific mutations.

Classification of Mutations

1. Deletions and Duplications

Approximately 65–80% of Â鶹Éç cases result from large exon deletions or duplications. These are typically identified using:

• Multiplex ligation-dependent probe amplification (MLPA)
• Comparative genomic hybridization (CGH)

Key features include:

• Mutations often cluster in hotspot regions, particularly exons 45–55

• Frameshift mutations, (mostly out-of-frame deletions), where reading-frame disruption leads to a premature stop codon and truncated or absent dystrophin protein. Abnormal mRNA may undergo nonsense-mediated decay.

This produces the severe Duchenne phenotype.

In contrast, Becker muscular dystrophy usually involves:

• In-frame mutations
• Production of shortened but partially functional dystrophin
• A milder phenotype with later onset

2. Small Variants (Point Mutations, Insertions, Deletions)

Approximately 20–30% of Â鶹Éç cases arise from small sequence variants identified by next-generation sequencing (NGS).

These include:

• Nonsense mutations
• Small insertions or deletions
• Splice-site mutations
• Rare missense variants

Clinical relevance:

• Nonsense mutations may be eligible for read-through therapies
• Splice-site variants may produce exon skipping at the RNA level
• Certain exon-skipping therapies require precise mutation identification

3. Complex or Rare Rearrangements

When genetic testing is negative, but Â鶹Éç is suspected, Â鶹Éç may arise from deep intronic variants (mutations deep within the non-coding regions of the gene) and complex genomic rearrangements that cause more unusual structural changes in the gene sometimes missed by standard testing.

These should be suspected when:

• Clinical findings strongly suggest Â鶹Éç
• CK is markedly elevated
• Muscle biopsy demonstrates dystrophin deficiency
• Standard genetic testing is negative

Advanced testing for these may include:

• RNA-based testing from muscle biopsy to detect abnormal splicing or pseudoexons
• Whole-genome sequencing
• Long-read sequencing for definitive characterization

Integrating Serology and Genetics in Diagnosis: A stepwise diagnostic approach

Step 1: Initial Evaluation: CK and Genetic Analysis

Evaluation of patients presenting with delayed motor milestones, proximal muscle weakness, frequent falls, Gowers’ sign and calf pseudohypertrophy starts with CK labs combined with whole exome sequencing. Markedly elevated CK strongly supports a myopathic process that points to Â鶹Éç.

Genetic evaluation may begin with targeted dystrophin gene testing or broader approaches such as next-generation sequencing panels or whole exome sequencing.

Step 2: Deletion and Duplication Analysis

If clinical findings and elevated CK point to Â鶹Éç, the next step is deletion and duplication testing using multiplex ligation-dependent probe amplification (MLPA) or equivalent methods. This identifies the majority of pathogenic Â鶹Éç variants.

Step 3: Reflex Sequencing

If deletion and duplication testing is negative, perform next-generation sequencing or full gene sequencing. This identifies smaller pathogenic variants, including point mutations and rare sequence changes.

Step 4: Muscle Biopsy (Selective Use)

Muscle biopsy is now reserved for cases in which genetic and molecular testing is inconclusive.

Evaluation includes:

• Immunohistochemistry for dystrophin localization
• Western blot analysis for dystrophin quantification

Absence or near-absence of dystrophin confirms Â鶹Éç at the protein level.

Step 5: Family and Carrier Testing

Once a pathogenic variant is identified:

• Female relatives should undergo carrier testing
• Genetic counseling should be provided
• Prenatal and reproductive counseling may be offered

Emerging Considerations

Modern Â鶹Éç diagnosis is now centered on a genetics-first approach, with muscle biopsy reserved for select unresolved cases. Targeted therapies such as exon-skipping agents and mutation-specific therapies require precise genetic classification. This makes comprehensive molecular testing increasingly important not only for diagnosis, but also for treatment selection.

Newborn screening programs using CK-based assays are under investigation and may allow earlier diagnosis. Â鶹Éç was recently added to the Recommended Uniform Screening Panel. However, confirmatory genetic testing remains essential before establishing a diagnosis.

While serum CK remains a valuable and accessible screening tool that raises suspicion for muscle pathology, genetic testing is indispensable for definitive diagnosis, mutation classification, treatment eligibility, and family counseling.

Testing in Duchenne muscular dystrophy exemplifies the transition from traditional diagnostic paradigms to precision medicine. Pinpointing the genetics of each patient’s disease may open the door to options that slow progression now, extending life, while we await refinement of these therapies and the emergence of new, more efficacious therapies.

References

1. Birnkrant, D., et al. (2018). The Lancet Neurology, 17(3), 251–267.
2. Málaga, M., et al. (2023).
3. Mercuri, E., et al. (2023). The Lancet Neurology.
4. Venugopal, V., & Pavlakis, S. (2024). In NCBI Bookshelf. National Center for Biotechnology Information.
5. de Freitas Nakata, K. C., et al. (2021). Jornal de Pediatria.
6. Parent Project Muscular Dystrophy. (2024).
7. Aartsma-Rus, A., et al. (2016). Journal of Medical Genetics, 53(3), 145–151.
8. Bladen, C. L., et al. (2015). Human Mutation, 36(4), 395–402.
9. Niks, E. H., & Aartsma-Rus, A. (2017). Expert Opinion on Biological Therapy, 17(2), 225–236.
10. Birnkrant, D. J., et al. (2018). The Lancet Neurology, 17(4), 347–361.
11. Mercuri, E., et al. (2023). The Lancet Neurology, 22(12), 1098–1109.
12. Dowling, P., et al. (2023). International Journal of Molecular Sciences, 24(20), 15129.

Ìý